In 2012, there were about 14 million new cases of cancer around the world. Of which, 6.7 million cases were of women, and 7.4 million cases were of men. These numbers are likely to increase to 24 million by 2035, reported the World Cancer Research Fund.
An estimated 8.2 million deaths that occurred in 2012 were directly related to cancer. The number of new cancers are also likely to rise by a rated 70 percent over the next two decades, according to the World Health Organization.
Shutting Nrf1 can Reduce Resistance to Blood Cancer Drugs
A protein called nrf1 causes resistance to drugs for blood cancers, but now researchers have found a possible workaround to shut nrf1 down.
Advertisement
‘Early detection and treatment can reduce cancer mortality, and the development of advanced therapeutic modalities have benefited from the anti-cancer drugs market.’
Tweet it Now
In 2012, about 13 percent of the total number of new cases diagnosed was lung cancer, which is the most common cancer across the world, followed by breast cancer - 1.7 million new cases, and colorectal cancer cases were 1.4 million.
Early detection and treatment can reduce cancer mortality. Diagnosing the disease at the right time could be the key to a useful and adequate treatment of the disease.
![Novel Mechanism of Resistance to Anti-Cancer Drugs Found]( "Novel Mechanism of Resistance to Anti-Cancer Drugs Found")
Epigenetic regulation to increase Wnt signaling may be a general mechanism cancer cells use to overcome therapeutic blockade of EGFR signaling.
The global anti-cancer drugs available in the market today can be accounted for the enormous amount of innovation that could transform the scene for patients, providers, and companies.
In 1990, after diagnosis, only half of all cancer patients lived for five years, which has increased to two-thirds, as a result of consistent innovation in the anti-cancer drugs market. revealed SEER (Surveillance, Epidemiology, and End Results) survival statistics.
The report serves as a blueprint for all stakeholders in the anti-cancer drugs market. This report also gives them a fresh, objective, and accurate perspective of the global industry and further examines the key factors administering its growth from 2016 to 2024.
The rising global incidence of various cancers is the primary factor for increasing the demand for anti-cancer drugs.
Additionally, the development of advanced therapeutic modalities like targeted therapies, chemotherapy, immunotherapy, and hormonal therapies have benefited from the anti-cancer drugs market in the past few years.
Anti-cancer drugs market is predicted to benefit from the commercialization of follow-on-biologics and patent expiration of several blockbuster drugs, revealed the report.
In the development of anti-cancer drugs, extremely high costs are involved, and the threat of failure of the drugs, along with the side effects are the expected challenges in expanding the global market in the next few years.
However, government funds are likely to reduce the negative impact of these obstacles and continue launching the anti-cancer drugs market.
Source: Medindia
Novel Mechanism of Resistance to Anti-Cancer Drugs Found
Epigenetic regulation to increase Wnt signaling may be a general mechanism cancer cells use to overcome therapeutic blockade of EGFR signaling.
Advertisement
The global anti-cancer drugs available in the market today can be accounted for the enormous amount of innovation that could transform the scene for patients, providers, and companies.
In 1990, after diagnosis, only half of all cancer patients lived for five years, which has increased to two-thirds, as a result of consistent innovation in the anti-cancer drugs market. revealed SEER (Surveillance, Epidemiology, and End Results) survival statistics.
The report serves as a blueprint for all stakeholders in the anti-cancer drugs market. This report also gives them a fresh, objective, and accurate perspective of the global industry and further examines the key factors administering its growth from 2016 to 2024.
The rising global incidence of various cancers is the primary factor for increasing the demand for anti-cancer drugs.
Additionally, the development of advanced therapeutic modalities like targeted therapies, chemotherapy, immunotherapy, and hormonal therapies have benefited from the anti-cancer drugs market in the past few years.
Anti-cancer drugs market is predicted to benefit from the commercialization of follow-on-biologics and patent expiration of several blockbuster drugs, revealed the report.
In the development of anti-cancer drugs, extremely high costs are involved, and the threat of failure of the drugs, along with the side effects are the expected challenges in expanding the global market in the next few years.
However, government funds are likely to reduce the negative impact of these obstacles and continue launching the anti-cancer drugs market.
Source: Medindia
Most New Cancer Drugs Lack Clinically Meaningful Benefits
Regulatory evidence standards are failing to incentivise cancer drug development that best meets the needs of patients, clinicians, and healthcare systems.
Advertisement
 Target of Anticancer Drugs Have Broader FunctionsHistone deacetylases (HDACs) are the drugs that inhibit the activity of enzymes. They are being widely developed for treating cancer and other diseases, with two already on the market. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.